Insomnia is among the most common sleep disorders worldwide, and its consequences reach well beyond a rough morning. People with insomnia struggle to fall asleep, to stay asleep through the night, or to wake feeling genuinely refreshed, and the disorder can severely degrade quality of life. Perhaps most importantly, chronic insomnia leaves people substantially more vulnerable to developing anxiety and depression over time, making effective treatment a genuine public health priority. Existing options include cognitive behavioural therapy, which is often recommended as a first-line approach, alongside pharmacological treatments such as antidepressants and antipsychotics, but the success of these interventions varies considerably from patient to patient. It is against this backdrop of imperfect alternatives that interest in medical cannabis has surged.

In clinical settings, medical cannabis is not the same product that consumers encounter in dispensaries. Prescribed cannabis medicines typically involve controlled, laboratory-tested ratios of the two best-known cannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD), delivered in standardised forms such as tablets, sprays or oils. This standardisation is intended to give clinicians predictable doses and compositions. Anecdotal reports and marketing have long touted cannabis as a sleep aid, and the drug’s sedating reputation has made it an appealing candidate for people desperate for rest. Yet the use of medical cannabis for insomnia remains contentious among sleep researchers and clinicians, and the formal evidence base has been thin.

To resolve that uncertainty, the review team systematically assembled the available randomised evidence. The review included nine studies involving 537 adults aged 18 to 76 who were treated for insomnia. Most of the studies focused on people with primary insomnia rather than insomnia linked to other health conditions, a distinction that matters because comorbid insomnia is often harder to treat and mechanistically different. Eight of the nine trials compared regulated medical cannabis against a placebo, the gold-standard design for determining whether a treatment outperforms expectation effects. The ninth trial took a different approach, comparing medical cannabis against amitriptyline, an antidepressant with sedating properties that is sometimes used off-label for sleep.

The headline result is stark in its modesty. Medical cannabis showed little to no clinically meaningful improvement in sleep quality and satisfaction, total sleep time, or daytime functioning compared with placebo. In other words, on the outcomes that matter most to patients with insomnia, how well they slept and how they functioned during the day, the drug did not demonstrate a clear advantage over an inert comparison. For a treatment whose reputation rests almost entirely on its perceived sleep benefits, this is a significant setback, and it suggests that the anecdotes driving cannabis’s popularity may not survive the scrutiny of controlled trials.

Safety signals added further concern. Participants taking medical cannabis were substantially more likely to experience mild adverse events, such as dry mouth and dizziness, than those receiving placebo. These effects are not dangerous in the way that some drug side effects can be, but they are not trivial for patients weighing whether a treatment is worth taking. Importantly, the review authors note that this safety conclusion was based on a small pool of studies, which means the true rate of adverse events remains imperfectly characterised. Even so, a treatment that shows no clear benefit while increasing the likelihood of side effects faces an unfavourable risk-benefit calculus.

There was one apparent bright spot: medical cannabis somewhat improved quality of life in the pooled analyses. But the reviewers urge heavy caution here. The certainty of this finding was rated very low, and the pooled results were compatible with anything from a slight worsening to a large improvement. That enormous range of plausible effects is a hallmark of unreliable evidence, and it means patients and clinicians cannot reasonably conclude from this dataset that cannabis genuinely enhances quality of life for people with insomnia. The finding is best read as a signal of what better-designed trials might one day examine, rather than as a positive result in its own right.

Why is the evidence so shaky? The review team graded the overall quality and certainty of the evidence as very low to low, and the reasons are instructive for anyone trying to interpret medical research headlines. The underlying studies carried a high risk of bias, meaning flaws in their design or conduct may have distorted their results. Findings were inconsistent between trials, making it hard to generalise from any single study. Sample sizes were small, with the entire review resting on 537 participants across nine trials. The studies also varied considerably in the type of cannabis product used, which limited comparability across trials, since different formulations, cannabinoid ratios and delivery methods can plausibly produce different effects. Perhaps most limiting of all, the longest study followed participants for only 12 weeks, leaving the long-term effects of cannabis treatment for insomnia essentially unknown.

There is also a representativeness problem that the reviewers highlight. The available data were heavily skewed towards younger people and women, who made up 72.66 percent of participants. As a result, the findings may not apply as well to men, to older adults, or to people with comorbid health conditions, groups that represent a large share of real-world patients seeking treatment for sleep problems. Clinicians hoping to use this evidence to guide prescribing for an older patient with multiple health issues will find that the trials simply did not include enough people like them to say anything confident. This gap between trial populations and clinical populations is a recurring weakness in cannabis research, and it is one the review makes impossible to ignore.

The authors’ conclusion is measured but firm: the evidence remains weak and uncertain, and higher-quality research is needed before medical cannabis can be recommended for insomnia. Dr Lucia Varela, lead author of the study from the University of Manitoba in Canada, emphasised that the research currently available is not sufficient to reliably answer whether medical cannabis helps people with insomnia, adding that this does not mean the treatment is ineffective, but that based on current evidence no reliable conclusions about its effectiveness can be drawn for the general population. Dr Luis Garegnani, senior author from the Universidad Hospital Italiano de Buenos Aires in Argentina, advised that rather than viewing the findings as an endorsement or a rejection of medical cannabis, clinicians and patients should recognise the uncertainty and consider individual circumstances while better evidence is generated. All authors declared no commercial or non-commercial conflicts of interest relevant to the review. For now, the message for the millions of people struggling with sleepless nights is not that cannabis cannot work, but that no one yet knows whether it does, and the only honest response to that uncertainty is more rigorous science.

Subject of Research: Medical cannabis as a treatment for insomnia

Article Title: Insufficient evidence to back medical cannabis for insomnia

Article References: Insufficient evidence to back medical cannabis for insomnia. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: medical cannabis, insomnia, Cochrane review, sleep quality, THC, CBD, systematic review, placebo, evidence quality, sleep disorders, clinical trials, daytime functioning

The review, published in the Cochrane Database of Systematic Reviews under the title Pharmaceutical industry information and promotional strategies aimed at prescribers, compiled observational data on prescribers who had received various forms of industry contact, including advertising and education, gifts and payments, and free samples. The technical strength of a Cochrane review lies in its systematic approach: the authors searched, appraised and synthesized studies according to predefined criteria, allowing patterns to emerge across heterogeneous settings rather than relying on any single investigation. What emerged was a coherent signal that exposure to industry promotion changes behavior in measurable ways, shifting prescribing toward promoted products and, in a substantial share of cases, away from prescribing that best serves patients clinically or economically.

Grundy, who also directs the WHO Collaborating Centre for Governance, Accountability, and Transparency in the Pharmaceutical Sector at the University of Toronto and is one of two Canadian authors on the review, emphasizes that these marketing tactics are not confined to any single country or regulatory environment. The same multi-national companies market their drugs worldwide, meaning the dynamics documented in the review likely apply broadly across health systems. In the United States, where the Open Payments system requires companies to publicly report transfers of value to physicians, just over half of all licensed physicians have accepted a payment of some kind, including something as ordinary as a free meal. That figure, Grundy notes, cuts two ways. It shows that companies concentrate their marketing resources on physicians expected to deliver the highest return on investment and to prescribe more of the promoted drug, but it also reveals that a large number of physicians deliberately choose not to interact with pharmaceutical companies at all and remain independent of these influences.

The economics of this influence deserve particular scrutiny. When physicians accept payments or meals, the data show they subsequently prescribe more of the promoted drug, and when that drug is a brand-name product with cost-effective alternatives available, the consequences ripple outward through the health system. Patients face higher co-pays and greater out-of-pocket costs, while payers and public programs absorb inflated drug expenditures that may deliver no additional clinical benefit. In this sense, the review frames industry promotion not merely as an ethical concern about professional independence but as a measurable driver of health system costs and of inequities in what patients pay at the pharmacy counter.

Canada occupies a revealing position in this evidence base. No Canadian studies were included in the review, largely because the country lacks a mechanism to track how much pharmaceutical companies pay physicians and nurse practitioners, or why those payments are made. Unlike the United States, which maintains its public Open Payments database, Canada has no comparable transparency infrastructure at the national level. Grundy points out that surveys and qualitative research outside this review suggest free meals and payments are nonetheless likely common among Canadian prescribers, meaning the absence of Canadian data reflects a gap in transparency rather than an absence of the phenomenon itself. For policymakers, this is a concrete and actionable finding: a country cannot manage or evaluate influences it does not measure.

The review did not stop at documenting the problem. A subset of the included studies examined what happens when institutions adopt conflict-of-interest policies or restrict physician interactions with industry within practice settings such as medical schools and teaching hospitals. The results were encouraging. In environments where such policies were in place, physicians tended to prescribe less overall, or to prescribe more appropriate treatments, suggesting that structural safeguards can meaningfully mitigate the effects of promotional exposure. The review authors argue that more robust conflict-of-interest policies represent an important way forward, shifting the burden of independence from the individual conscience of each clinician to the systems in which care is delivered.

Grundy frames this as a matter of institutional responsibility rather than personal blame. Prescribers, she argues, need independent, evidence-based sources of drug information to maintain their independence in practice and to remain trustworthy and accountable to the people they serve. The studies included in the review demonstrate that practice environments can be deliberately designed to promote and preserve that independence, and that this is best achieved collectively, within health systems and institutions, rather than leaving individual clinicians to resist sophisticated, well-resourced marketing campaigns on their own. This reframing matters, because decades of research on professional behavior suggest that relying solely on individual willpower against systematic commercial pressure is a weak intervention compared with changing the environment itself.

There is also an important scope question raised by the findings. While most of the available research focused on physicians, physicians are no longer the only prescribers in many health systems, including Canada. Descriptive studies using the United States Open Payments data, which were not part of this review, have found that advanced practice nurses, including nurse practitioners and clinical nurse specialists, are also targets of industry promotion. As scope-of-practice expansions place more prescribing authority in the hands of nurses and other non-physician clinicians, the reach of pharmaceutical marketing expands with it. Grundy is explicit on this point: this is not just a problem for medicine, it affects the entire healthcare team, and the goal should be to create healthcare environments that safeguard the independence and integrity of care for every prescriber within them.

For readers weighing the practical implications, the review offers a clear evidence-based agenda. Health professional schools, hospitals, professional societies and health systems can adopt and enforce conflict-of-interest policies that limit promotional contact, particularly during training when prescribing habits are formed. Jurisdictions without transparency mechanisms, Canada among them, can establish mandatory disclosure of industry payments to all prescribers, not only physicians. Clinicians and educators can prioritize independent sources of therapeutic information. And patients, whose co-pays and out-of-pocket costs absorb much of the financial consequence, have a stake in demanding that prescribing decisions rest on clinical evidence rather than commercial relationships. The Cochrane evidence indicates that none of these changes requires a scientific breakthrough, only the institutional will to act on what the data already show.

What makes this review resonate beyond academic circles is its scale and its consistency. With evidence from more than 93 studies and the observed practices of millions of prescribers, the association between industry payments and prescribing behavior is no longer a contested curiosity of health services research; it is a documented, repeatable pattern across health systems and regulatory regimes. The finding that conflict-of-interest policies measurably improve prescribing adds a constructive counterweight, demonstrating that the influence of promotion is neither inevitable nor irreversible. As Grundy and her colleagues make clear, the task now is to translate that evidence into policy, so that the environments in which clinicians train and practice actively protect the independence on which safe, appropriate and affordable prescribing depends.

Subject of Research: The influence of pharmaceutical industry marketing and payments on physician prescribing behavior

Article Title: Study links pharmaceutical industry payments to changes in physicians’ prescribing practices

Article References: Study links pharmaceutical industry payments to changes in physicians’ prescribing practices. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pharmaceutical industry, prescribing practices, Cochrane review, conflict of interest, Open Payments, physician payments, drug marketing, health policy, inappropriate prescribing, healthcare costs, Quinn Grundy, University of Toronto

Pharmaceutical companies deploy a wide arsenal of strategies to promote their products to the people who write prescriptions. These include one-on-one visits by sales representatives to doctors’ offices and hospitals, paid meals, coverage of travel costs to conferences, entertainment, consulting fees, honoraria for serving on advisory boards, and direct advertising. For every new medicine brought to market, companies target prescribers with offers of free meals and other payments, and the review confirms that these interactions translate into prescribing of the promoted drug, even when that drug may not be needed or may not be the most suitable or affordable option for a particular patient.

The evidence base behind the review is notable for its scale and its real-world grounding. The 93 included studies spanned several different study designs, but almost all of them observed actual prescribing patterns in clinical practice rather than relying on controlled experiments. The overwhelming majority of the studies, 88 percent, came from the United States, a concentration the authors attribute in part to the Physician Payments Sunshine Act of 2010. That legislation requires pharmaceutical companies to publicly report all payments made to doctors, and the resulting data is compiled in a searchable, analyzable database that has made it possible for researchers to link industry spending to prescribing behavior at an unprecedented level of detail.

To bring order to this vast body of data, the review authors grouped industry interactions into three distinct categories: advertising and education, gifts and payments, and free drug samples. They also examined conflict-of-interest policies as a potential mitigation strategy. The evidence was strongest and most consistent for gifts and payments, which were linked to less appropriate prescribing, a higher volume of prescriptions, and probably increased costs. Advertising and education, including sales representative visits, appeared to be associated with prescribing that was less clinically suitable and more expensive, with fairly strong evidence that these activities also drove up the overall number of prescriptions written. For free drug samples, and for the question of whether promotion influences hospital formulary decisions, the available evidence was too sparse or weak to support firm conclusions, although the limited data that does exist hints at possible effects.

One of the most striking patterns the review uncovered is a clear dose-response relationship between paid meals and inappropriate prescribing. The more meals a doctor received from a particular company, the more of that company’s drug the doctor prescribed. Crucially, this relationship held across a wide range of drug classes, from medications for high blood pressure and high cholesterol to antidepressants and opioid painkillers. A dose-response relationship is considered a hallmark of a genuine causal effect in epidemiological research, because it is difficult to explain by confounding factors why increasing exposure should predict increasing outcome so consistently across unrelated therapeutic areas.

Dr. Lisa Bero of the University of Colorado Anschutz, a study author, summarized the central finding bluntly: overall, when doctors have more contact with drug company promotion, prescribing tends to become less appropriate, more frequent, and more expensive. She emphasized that this matters because it directly affects patient care, noting that less appropriate and more expensive drugs can offer fewer benefits or cause more side effects than the alternatives, or may simply be unnecessary in the clinical context. In other words, the harms are not abstract financial ones; they can translate into worse outcomes for the individual patients sitting in the exam room.

No example illustrates the potential consequences of pharmaceutical promotion more starkly than the opioid crisis. The review found that even inexpensive meals were associated with increased opioid prescribing, and that the more payments a doctor received from opioid manufacturers, the more likely that doctor was to prescribe dangerously high opioid doses. The widespread inappropriate overprescribing of opioids, driven in part by marketing that exaggerated benefits and minimized harms, contributed to an epidemic of addiction and overdose deaths in North America. Dr. Bero described the opioid crisis as perhaps the most egregious example of inappropriate over-prescribing, but stressed that it was not an isolated incident. It attracted attention because the harms were so visible and severe, yet she argued that the systems which enabled it are still considered business as usual within the industry, and that interactions between pharmaceutical companies and prescribing physicians remain widespread while the harms they cause are rarely so apparent.

The normalization of these practices within medicine itself is a recurring theme in the research. Dr. Barbara Mintzes of the University of Sydney, the lead author, pointed out that receiving free meals from companies is very common for doctors, and that many physicians regard the practice as trivial and personally non-influential. Doctors often believe they cannot be bought for the price of a sandwich, she observed, but the data tells a different story: the more free meals a doctor receives, the more likely they are to prescribe less appropriate or more expensive drugs. From a marketing standpoint, the evidence suggests that small, routine gestures are an effective and efficient strategy, precisely because prescribers underestimate their own susceptibility.

There is, however, an encouraging counterpoint in the findings. Some hospitals and medical centers have adopted institutional restrictions, commonly known as conflict-of-interest policies, that limit how much contact industry representatives can have with doctors or what gifts and samples they are permitted to provide. The review found that these policies can mitigate the negative impact of pharmaceutical marketing on prescribing habits. According to Dr. Mintzes, robust conflict-of-interest policies tended to be effective, with the data indicating that they probably improve prescribing appropriateness and possibly reduce the overall number of prescriptions. This gives policymakers, hospital administrators, and professional bodies a concrete, evidence-supported lever for reform.

The authors are careful to frame the problem as one of systems rather than individuals. The review’s message, they emphasize, is not that a few bad apples are corrupting the profession, but that the structure of industry-prescriber interaction itself skews clinical decisions in ways that conflict with patient interests. With evidence now spanning millions of prescribers, multiple drug classes, and a dose-response gradient linking meals to prescriptions, the case for stricter institutional policies has grown considerably stronger. For patients, the practical takeaway is that the most appropriate treatment should be chosen on the basis of clinical evidence rather than industry marketing, and for the medical profession, the review suggests that the price of a sandwich may be higher than anyone imagined.

Subject of Research: The influence of pharmaceutical industry marketing on physician prescribing behavior

Article Title: Pharmaceutical company marketing negatively influences prescribing

Article References: Pharmaceutical company marketing negatively influences prescribing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pharmaceutical marketing, prescribing behavior, Cochrane review, conflict of interest, opioid crisis, free meals, Sunshine Act, drug promotion, systematic review, health policy, sales representatives, patient safety

The findings carry considerable weight because of the rigor behind them. Cochrane reviews are systematic analyses designed to synthesize the best available research in a way that can directly guide clinical care, and this review is described as the most comprehensive of its kind to date. The work was supported by the Exeter NIHR Biomedical Research Centre, the Dennis and Mireille Gillings Foundation, and the Bateman Family Charitable Trust. Rather than relying on any single trial, the researchers pooled the worldwide evidence on multifactorial interventions, programs that assess an individual person’s specific risk factors and then assemble a customized package of treatments, which might combine exercise with medication changes, home hazard removal, or other targeted measures.

The scale of the problem these programs are meant to address is enormous. Falls are among the most common causes of injury and death in older people worldwide. Roughly one in three people aged over 65 experiences at least one fall each year, and 684,000 falls are reported annually. Beyond the immediate injuries, falls can trigger a cascade of consequences, from fractures and hospitalization to loss of confidence, reduced mobility, and accelerating frailty. For an ageing global population, preventing falls is not a niche clinical concern but a central public health challenge, which is precisely why the review’s conclusions are likely to provoke debate among clinicians, policymakers, and researchers.

To understand why the results matter, it helps to distinguish between the different types of interventions that have been developed over the years. Some fall prevention approaches involve a single type of treatment, such as exercise programs designed to build muscle strength and improve balance. Others combine two or more treatments, for example exercise alongside changes to medication. A third category, the multifactorial programs at the heart of this review, goes a step further by tailoring the combination of treatments to an individual’s assessed level of risk, such as arranging home hazard removals for people whose living environments are judged particularly dangerous. The intuition behind personalization is appealing: match the intervention to the person, and the intervention should work better.

The review’s analysis, however, undercuts that intuition in important ways. The researchers found that multifactorial programs are less effective than cheaper options such as delivering good education to prevent falls. When the tailored programs were compared with usual medical care, they only slightly reduced the rate of falls or the risk of falling again. When they were compared with exercise, the evidence was even less decisive: it remains unclear whether multifactorial programs reduce the rate of falls or the risk of falling again at all in that comparison. In other words, the added complexity and cost of individualized assessment and customized treatment packages did not translate into clearly superior outcomes.

The review also examined a related category of interventions known as multi-component treatments, which include a range of factors but are not personalized to individual risk. Here too the findings were sobering. Multi-component programs showed little or no benefit in how often people fall when compared with usual medical care, exercise, or falls prevention education. Taken together, the results suggest that the assumption underlying decades of fall prevention practice, that more components and more personalization necessarily mean more protection, may simply not hold up under systematic scrutiny.

There is, however, an important nuance. The review concluded that there may be a small benefit in the number of falls and in the risk of falling again when tailored programs were compared with usual care. The effects, though, were much smaller when the same programs were measured against exercise or falls prevention education. That distinction matters enormously for health systems operating under constrained budgets. If a simple, low-cost educational intervention performs as well as or better than an elaborate personalized assessment program, the rational allocation of limited resources becomes difficult to justify on the side of complexity. This is the practical dilemma the Exeter team places squarely before clinicians and commissioners.

Dr Lianne Wood, Bateman Family Chair in Peripheral Neuropathy at the University of Exeter Medical School and co-lead author of the review, framed the findings in terms of the responsibility health services bear to their populations. In an ageing society, she noted, effectively preventing falls can save lives and help people live healthier lives for longer, and because health services operate on limited funding, decisions must be guided by the best available evidence. She emphasized the sheer volume of research in the field, explaining that the review was deliberately designed to find answers about what really works. Dr Cynthia Swarnalatha, also of the University of Exeter Medical School and co-lead author, described the team’s surprise at discovering that many of the more complex programs did not measure up. She pointed to effective education and the encouragement of exercise uptake as simpler approaches that the review found to have potentially the most benefit in falls prevention.

Professor Sarah (Sallie) Lamb, Mireille Gillings Professor of Health Innovation at the University of Exeter and co-author, offered a perspective on what the results reveal about the state of the science. The findings, she said, show how much remains to be learned about how and why falls happen in the first place. Her team is now conducting a major study aimed at understanding why people develop unstable walking and face higher risks of falls. Combined with the review, she argued, that work will help researchers design the best prevention programs in the future, with the broader goals of reducing frailty and helping people live well for as long as possible. This forward-looking research agenda suggests the field may be on the verge of a more fundamental rethinking of fall prevention, moving from assembling packages of interventions toward understanding the underlying mechanisms of instability.

For now, the practical message of the review is likely to be uncomfortable for some and liberating for others. It challenges the assumption that sophisticated, individualized programs are inherently superior, and it elevates two humble tools, clear education and exercise, to the top of the evidence hierarchy. For older people and their families, the takeaway may be encouraging: the interventions with the strongest support are also among the most accessible. For health services, the review provides an evidence-based mandate to question whether expensive multifactorial assessments deliver value commensurate with their cost. And for researchers, it issues a challenge to explain why personalization, so effective in other areas of medicine, has not yet proven its worth in preventing one of the most common and consequential hazards of ageing. As populations continue to age worldwide, the answers to those questions will shape not only health budgets but the quality of life of millions of people hoping to stay steady on their feet.

Subject of Research: Effectiveness of multifactorial and multi-component interventions for preventing falls in older people living in the community

Article Title: Personalized programs to prevent falls may make no difference: Cochrane review

Article References: Personalized programs to prevent falls may make no difference: Cochrane review. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: falls prevention, Cochrane review, older people, multifactorial interventions, exercise, health economics, University of Exeter, systematic review, ageing, frailty, public health, evidence-based medicine

The immediate trigger for Owen’s intervention is a recent Cochrane systematic review, led by Nonino and colleagues, which concluded that amyloid-beta-targeting monoclonal antibodies offer no clinically meaningful benefit to people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The review’s publication provoked sharp criticism from within the Alzheimer’s research community, but Owen observes that much of that criticism focused on the review’s methodology, on questions of statistical pooling, trial selection and effect-size calculation, rather than on the underlying clinical case for the drugs themselves. In his view, this deflection represents a missed opportunity. Rather than interrogating whether the treatments help patients in ways that matter in daily life, the debate has circled technical questions that leave patients, families and clinicians without a clear answer.

At the heart of the controversy lies a deceptively simple question: what does a ‘modest’ or ‘moderate’ benefit actually mean for a person living with early Alzheimer’s disease? The pivotal trials of lecanemab, reported in the New England Journal of Medicine by van Dyck and colleagues in 2023, and of donanemab, reported in JAMA by Sims and colleagues in the TRAILBLAZER-ALZ 2 trial, both demonstrated statistically significant slowing of decline on the Clinical Dementia Rating Scale Sum of Boxes, a standard instrument for staging dementia that was first described by Hughes and colleagues in 1982. But statistical significance is not the same as clinical meaning. A change on a rating scale, even one that reaches conventional thresholds for significance, may translate into differences in daily functioning that are imperceptible to patients and their caregivers, or it may not. Owen’s Comment presses precisely on this gap between the numbers reported in trial publications and the lived reality of the disease.

The problem of defining clinically meaningful outcomes is not unique to Alzheimer’s research, but it is unusually acute there. A 2025 review by Stoeckel and colleagues examined what constitutes clinically meaningful outcomes in Alzheimer’s disease and related dementia trials, and a 2024 rapid review by Muir and colleagues tackled the related concept of the minimal clinically important difference in the disease. Both underline a persistent difficulty: the field has lacked consensus on how large an effect must be, and on which measures, before it can honestly be described as beneficial to a patient. Without such consensus, terms like ‘modest’ and ‘moderate’ float free of any anchor, allowing advocates and skeptics to describe the same trial results in dramatically different terms. Owen argues that this ambiguity is not an accident of imprecise language but a structural feature of how the field has communicated its results, and one that has gone largely unexamined.

One way to calibrate expectations is to compare the anti-amyloid drugs against other interventions whose effects are better understood. Cognitive training and cognitive stimulation therapies, which aim to maintain or improve thinking skills through structured mental activity, have been studied for decades with rigorous randomised controlled designs. Work by Huntley, Hampshire and Owen himself in 2017 tested adaptive working memory strategy training in early Alzheimer’s disease, and broader meta-analyses by Zhang and colleagues in 2019 and Chan and colleagues in 2024 have synthesised the effects of computerised cognitive training in mild cognitive impairment. Cochrane reviews by Bahar-Fuchs and colleagues and meta-analyses of cognitive stimulation therapy by Desai and colleagues and by Spector and colleagues provide further benchmarks. These interventions produce effects on cognitive measures that are, in many cases, comparable in magnitude to those reported for anti-amyloid antibodies, yet they are rarely described in the triumphant language that has accompanied the new drugs. That asymmetry, Owen suggests, is itself informative about how the field weighs evidence.

The history of the amyloid programme also includes sobering episodes that complicate the narrative of steady progress. Aducanumab, the first anti-amyloid antibody to receive accelerated approval, was discontinued as an Alzheimer’s treatment, a decision acknowledged by the Alzheimer’s Association, after a trajectory marked by contested trial results and contentious regulatory review. A 2022 analysis by Kim and colleagues catalogued key insights from two decades of clinical trial failures in Alzheimer’s disease, a record that spans far more than amyloid-targeting agents and reflects the extraordinary difficulty of intervening in a neurodegenerative process that begins years before symptoms appear. Against that backdrop, the licensing of lecanemab and donanemab, with the United States Food and Drug Administration converting one novel treatment to traditional approval in September 2025, represents genuine scientific progress in the narrow sense that amyloid can now be reliably cleared from the brain. The open question is whether plaque removal, on its own, changes the course of the disease in ways patients can feel.

Owen’s Comment also situates the current debate within the broader architecture of Alzheimer’s diagnosis and drug development. Revised criteria for the diagnosis and staging of Alzheimer’s disease, published by Jack and colleagues in 2024 under the auspices of the Alzheimer’s Association Workgroup, have moved the field toward a biological definition of the disease, in which biomarkers of amyloid and tau pathology can establish a diagnosis even in the absence of symptoms. That shift has been celebrated as a way to intervene earlier, before irreversible neuronal loss occurs, but it also raises the stakes of the benefit question: if treatments are to be offered to ever larger populations identified by biomarkers rather than symptoms, the size of the benefit each patient can expect becomes a matter of profound practical importance. The drug development pipeline, surveyed by Cummings and colleagues in 2025, remains crowded with agents, and the proportion of the population carrying risk variants such as APOE4, estimated in pooled analyses of nearly 389,000 community-dwelling individuals by Wang and colleagues, underscores the scale of the population that stands to be affected by these decisions.

What makes Owen’s argument distinctive is not a claim that the trials were flawed or that the drugs are useless, but a call for honesty about the magnitude of their effects and for a vocabulary that patients and clinicians can actually use. The pivotal trials enrolled people with mild cognitive impairment or mild dementia, the earliest symptomatic stages of the disease, precisely because that is where intervention is thought to hold the most promise. In those populations, the reported slowing of decline, while statistically robust, must be weighed against practical realities: the drugs require regular intravenous infusions over extended periods, monitoring with magnetic resonance imaging for a serious side effect known as amyloid-related imaging abnormalities, and careful patient selection. For a patient and family deciding whether to commit to that regimen, the relevant question is not whether a p-value crossed a threshold but whether the treatment will meaningfully extend the time they can live independently, recognise loved ones, or continue the activities that give their lives structure and meaning. Owen contends that the field has not done the work of answering that question in those terms.

The Comment also highlights a striking feature of the public response to the Cochrane review: the speed and intensity with which it was challenged by patient organisations and leading experts, including a public response from the Alzheimer’s Society defending the anti-amyloid drugs as effective. In a field that has endured repeated disappointments, the desire for treatments that finally work is entirely understandable, and patient advocacy has historically been a powerful force for accelerating research and improving access to care. But Owen’s concern is that advocacy, however well intentioned, can short-circuit the kind of critical self-examination that science requires. If the conversation about clinical meaningfulness is framed as an attack on hope rather than as a legitimate scientific question, then the field loses the opportunity to establish, once and for all, what its therapies can and cannot do, and to design the next generation of trials around outcomes that matter.

The stakes of this unresolved conversation extend well beyond the current generation of antibodies. If the field cannot agree on what constitutes a clinically meaningful benefit, then even genuinely transformative therapies of the future may struggle to demonstrate their value, and patients may continue to face difficult decisions armed only with vague descriptors and contested statistics. Owen’s contribution, published as a Neurological Update in the Journal of Neurology and supported by the Canadian Institutes of Health Research, is ultimately an appeal for clarity: for researchers, regulators and clinicians to specify, in concrete and patient-centred terms, what ‘modest’ and ‘moderate’ benefit mean, and to have that discussion openly rather than allowing it to remain the conversation the Alzheimer’s field isn’t having. Whether the field takes up that challenge will shape not only how the current drugs are used, but how the next decades of Alzheimer’s research are judged by the people who matter most, the patients and families living with the disease.

Subject of Research: Clinical meaningfulness of anti-amyloid monoclonal antibody therapies in Alzheimer's disease

Article Title: What have trials targeting amyloid in Alzheimer’s told us to date? The conversation the Alzheimer’s field isn’t having

Article References: Owen, A. M. (2026). What have trials targeting amyloid in Alzheimer’s told us to date? The conversation the Alzheimer’s field isn’t having. Journal of Neurology, 273(10), Article 617. https://doi.org/10.1007/s00415-026-14147-8

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14147-8

Keywords: Alzheimer's disease, anti-amyloid therapies, lecanemab, donanemab, Cochrane review, clinical trials, clinical meaningfulness, amyloid-beta, dementia, cognitive training, biomarkers, drug development